Bristol-Myers Squibb Company (BMY) investor relations material

Strategic vision and portfolio priorities

• Focus on science, execution, and value to drive innovation in hematology, leveraging deep expertise and AI to accelerate R&D and maximize clinical success.

• Portfolio discipline ensures resources are allocated to the most promising, differentiated assets across all therapeutic areas.

• Decades of leadership in hematology, with a rich pipeline spanning multiple myeloma, leukemias, lymphomas, and anemia.

Pipeline highlights and clinical data

• CELMoDs iberdomide and mezigdomide show strong efficacy and safety in multiple myeloma, with pivotal trials ongoing and data readouts expected in the next 12-24 months.

• Arlo-cel, a GPRC5D-targeting CAR-T, demonstrates high response rates and manageable safety in heavily pretreated myeloma patients, with pivotal studies underway.

• Dual-targeting BCMA and GPRC5D CAR-T aims to prevent relapse and offer curative potential, with first clinical data anticipated next year.

• Golcadomide and BCL6 ligand-directed degrader show promising efficacy and safety in lymphoma, supporting ongoing phase III and combination studies.

Regulatory and commercial outlook

• Regulatory strategy includes both single-arm and randomized controlled trials for CAR-T assets, with flexibility in FDA negotiations.

• CELMoDs positioned to replace IMiDs as backbone therapies in myeloma, offering improved potency, tolerability, and combinability.

• Breyanzi has become the leading CD19 CAR-T globally, driven by efficacy, safety, and expanded market access, with continued growth expected.

• No significant pricing or reimbursement challenges reported for Breyanzi or CELMoDs, with strong uptake in both academic and community settings.